ALZN News

The IPO market was in full swing this past week as 16 IPOs and six SPACs went public. The IPO pipeline cooled down with just one IPO and nine SPACs submitting initial filings. The largest deal of the week, Lyell Immunopharma (LYEL) priced at the midpoint to raise $425 million at a $4.7 billion market cap. The company is using proprietary genetic and...read more

Alzamend Neuro, a preclinical biotech developing therapies for Alzheimer's disease, raised $12.5 million by offering 2.5 million shares at $5, as expected. The company noted in its prospectus that an affiliate of founder and Executive Chairman Todd Ault may buy up to $10 million of the IPO. Lead candidate AL001 is an ionic cocrystal of lithium for the treatment of...read more

Alzamend Neuro, a preclinical biotech developing therapies for Alzheimer's disease, announced terms for its IPO on Tuesday. The Tampa, FL-based company plans to raise $12.5 million by offering 2.5 million shares at $5 per share. Insider Digital Power Lending, a subsidiary of CEO-affiliated Ault Global Holdings, intends to purchase $10 million worth of shares in the offering, or...read more

The IPO market had a tumultuous week with five IPOs and three postponements: Brazilian customer service platform Zenvia (ZENV), mortgage insurance spinoff Enact Holdings (ACT), and hearing care services provider hear.com (HCG). SPAC activity remained steady, with two blank check IPOs raising $430 million. New filers continued...read more